Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Overview and Financial Insights

H.C. Wainwright sets a price target of $620 for MDGL, indicating a potential increase of approximately 10.99%.Madrigal Pharmaceuticals announces the granting of equity awards to three new non-executive employees as part of its 2025 Inducement Plan.MDGL's current trading price of $563.96 reflects a 4.03% rise, showcasing significant volatility and trading activity.Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated ...